Kiromic Biopharma Inc (KRBPQ)

Kiromic BioPharma, Inc. is a Houston, Texas-based clinical-stage biotechnology company listed on OTC Markets as common stock. The company has focused on developing allogeneic gamma delta T-cell therapies for solid tumors, with programs built around non-engineered and engineered GDT cell technologies. Its pipeline has included Deltacel-01, a Phase 1 candidate being studied with low-dose targeted radiation in non-small cell lung cancer, as well as Isocel and Procel, which have been evaluated in clinical trials for mesothelin Isoform 2 positive and PD-L1 positive solid malignancies, respectively. The company has also conducted related ALEXIS-ISO-1 and ALEXIS-PRO-1 studies. Kiromic Biopharma was founded in 2006 and changed its name from Kiromic, Inc. in December 2019. On March 21, 2025, it filed a voluntary Chapter 7 liquidation petition in the U.S. Bankruptcy Court for the District of Delaware.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.